Erwin Fadnavis
Chemotherapy-induced peripheral pathology (CIPN) has long been recognized as a clinically important issue in patients treated with antineoplastic medication. This common long-run poisonous side-effect that negatively impacts the result of the illness will result in incapacity and have prejudicial effects on patients’ quality of life.